iPSC programs extend well beyond NK cell therapies

Induced pluripotent stem cells are on the cusp of a major translational moment as biotechs advance more than 20 types of cell therapies derived from the renewable cell source. With a large number of players poised to enter the clinic, the field may soon start homing in on the best proof-of-concept applications and development strategies for the new modality.

Natural killer (NK) cell therapies have emerged as the leading application for induced pluripotent stem cell (iPSC)-derived therapies, but biotechs — and a few pharmas — are using the cells to create at least 20 other cell types ranging from neurons to hair follicles...